ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 阿尔茨海默病神经影像学倡议（ADNI）是一项为期5年的NIA倡议，旨在测试是否可以将系列磁共振成像（MRI），正电子发射断层扫描（PET），其他生物标志物以及临床和神经心理学评估结合起来，以测量轻度认知障碍（MCI）和早期阿尔茨海默病（AD）的进展。ADNI将比较来自研究参与者的神经影像学、生物学和临床信息，寻求数据之间的相关性，这些数据将从最早阶段跟踪记忆丧失的进展。 将在美国和加拿大的50个研究中心共招募800例受试者。每次扫描时，受试者将接受临床和神经心理学评估。所有受试者将接受重复的1.5T MRI扫描，25%将接受重复的3 T MRI扫描，50%将接受重复的PET扫描，扫描频率与1.5T MRI成像相同。从这项研究中学到的东西将用于帮助研究人员和临床医生开发新的治疗方法，并监测其有效性，提高药物开发的安全性和效率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a 5-year NIA initiative to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI will compare neuroimaging, biological and clinical information from study participants seeking correlations among the data that will track the progress of memory loss from its earliest stages. A total of 800 subjects will be recruited at 50 sites in the US and Canada. The subjects will undergo clinical and neuropsychological evaluations each time scanning is performed. All subjects will undergo repeated 1.5T MRI scanning, 25% will undergo repeated 3T MRI scanning, and 50% will undergo repeated PET scanning with the same frequency of scanning used for the 1.5T MRI imaging. What is learned from the study will be used to help researchers and clinicians develop new treatments and monitor their effectiveness, increasing safety and efficiency of medication development.